Biocon's subsidiary received marketing approval for its pegfilgrastim biosimilar in Japan.

Biocon LimitedBIOCON · Filed with the exchange

This strengthens Biocon's portfolio there.

Sandoz K.K. will exclusively promote and distribute the product, expanding patient access to high-quality, affordable medications.

No comments yet. Be the first.

More from Biocon Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.